Blog • 2025-11-07

Combination Oncology: The Dosing Challenge in Modern Cancer Care

How multi-agent cancer therapies create unprecedented dosing complexity—and why traditional approaches fall short.

The evolution of combination oncology

Combination therapies have fundamentally redefined oncology care over the past two decades. What began with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) for lymphoma has evolved into sophisticated multi-agent regimens combining targeted therapies, immunotherapies, and traditional chemotherapies. Today, it's common for cancer patients to receive three, four, or even five concurrent medications, each with distinct mechanisms of action, toxicity profiles, and dosing requirements.

This evolution has delivered remarkable outcomes—improved survival rates, better response rates, and new treatment options for previously untreatable cancers. But it has also introduced a fundamental challenge: how do you optimize dosing when multiple agents interact in complex, patient-specific ways?

The dosing complexity problem

Combination oncology creates three distinct but interconnected challenges:

Why current approaches are insufficient

Traditional oncology dosing relies heavily on phase I/II trial data that establishes maximum tolerated doses (MTDs) for individual agents. When combining agents, clinicians typically:

• Start with standard doses from monotherapy trials
• Reduce doses empirically if toxicity occurs
• Rely on clinical judgment to balance efficacy and safety

This approach has several limitations:

• Limited combination data: Most combinations haven't been studied in formal dose-finding trials, leaving clinicians to extrapolate from monotherapy data
• Reactive rather than predictive: Dosing adjustments happen after toxicity occurs, not proactively based on patient characteristics
• No regimen-level optimization: Each medication is considered in isolation, not as part of an integrated regimen
• Inconsistent rationale: Dose reductions often lack clear, evidence-based justification, making regulatory submissions and payer discussions challenging

The OptimDosing approach

OptimDosing's patented engine addresses these challenges by fitting individualized models using patient-level data and population evidence. Rather than starting with fixed doses and adjusting reactively, our system:

1. Models the full regimen simultaneously. The engine considers all medications together, accounting for pharmacokinetic interactions (how drugs affect each other's absorption, distribution, metabolism, and excretion) and pharmacodynamic interactions (how drugs affect each other's mechanisms of action).

2. Incorporates patient-specific factors. Age, performance status, organ function (kidney, liver, heart), genetic variants, and prior treatment history all influence dosing recommendations. A 75-year-old with reduced kidney function will receive different recommendations than a 45-year-old with normal organ function, even for the same cancer type and stage.

3. Produces optimized doses with safety bounds. Instead of a single "recommended dose," the system provides dose ranges with upper and lower bounds based on safety and efficacy objectives. This gives clinicians flexibility while maintaining safety.

4. Generates transparent rationale. Every recommendation includes supporting evidence, references to relevant studies, and clear explanation of why specific doses were chosen. This documentation is suitable for inclusion in clinical protocols and regulatory submissions.

Applications in oncology development and care

Regulatory and payer considerations

One of the key advantages of OptimDosing's approach is the transparent, evidence-based rationale it provides for dosing decisions. This documentation is valuable for:

• FDA submissions: Clear justification for dose selection in combination trials strengthens regulatory packages
• Payer discussions: Evidence-based dosing rationale supports coverage decisions, especially for expensive targeted therapies and immunotherapies
• Clinical guidelines: The systematic approach can inform guideline development for combination regimens

Looking ahead

As oncology continues to evolve toward more personalized, combination-based approaches, the need for sophisticated dosing optimization will only grow. The challenge isn't just managing toxicity—it's maximizing efficacy while maintaining quality of life, and doing so in a way that's scalable, reproducible, and evidence-based.

OptimDosing's patented technology represents a fundamental shift from empirical dose adjustment to model-driven optimization. By combining patient-specific data with population evidence, we enable clinicians and researchers to make dosing decisions that are both safer and more effective.

References

1. Mokhtari RB, et al. Combination therapy in combating cancer. Cancers. 2017;9(12):160.
2. Chen EX, et al. Optimizing combination therapy in oncology: challenges and opportunities. The Oncologist. 2025;30(2):145-152.